Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, ...

RAMAT GAN, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a ...

Timely remdesivir treatment in immunocompromised patients infected with COVID-19 is associated with improved survival outcomes.

While early diagnosis and treatment have significantly improved prostate cancer survival rates, it remains challenging to treat effectively in late ... This approach helps the treatment focus on ...

Revolution has set itself a mission to revolutionize treatment for patients with RAS addicted cancers. See why I upgrade RVMD ...

BIRMINGHAM, AL, USA I 4, 2024 I Treovir, Inc. announced today the opening of a Phase 2 trial testing G207, an oncolytic HSV immunotherapy, in ...